Raft of Japanese approvals includes Revolade and Byetta
This article was originally published in Scrip
Japan's ministry of health, labour and welfare has issued formal final approvals for a large number of new products and additional indications, including GlaxoSmithKline's oral thrombopoietin receptor agonist Revolade (eltrombopag) and Lilly/Amylin's GLP-1 agonist Byetta (exenatide).
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.